|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 May 2022 |
|
Main ID: |
NCT03440892 |
|
Date of registration:
|
14/02/2018 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients
SurviTreat |
|
Scientific title:
|
Longitudinal Observational Study on Rheumatoid Arthritis Patients: Effects of Antirheumatic Treatment on Serum Levels of Survivin |
|
Date of first enrolment:
|
November 1, 2017 |
|
Target sample size:
|
2500 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT03440892 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Sweden
| | | | | | | |
|
Contacts
|
|
Name:
|
Sofia T Silfverswärd |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
sofia.silfversward@rheuma.gu.se |
|
Affiliation:
|
|
|
|
Name:
|
Maria Bokarewa, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
maria.bokarewa@rheuma.gu.se |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients fulfilling the RA classification criteria according to the ACR/EULAR
Exclusion Criteria:
- Patients at stable/unchanged anti-rheumatic treatment
- Other serious physical or mental illness
- Lack of knowledge in Swedish making answering the questionnaires impossible
Age minimum:
20 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Rheumatoid Arthritis
|
|
Intervention(s)
|
|
Drug: sulfasalazine
|
|
Drug: tocilizumab
|
|
Drug: tofacitinib/baricitinib
|
|
Drug: methotrexate
|
|
Drug: abatacept
|
|
Primary Outcome(s)
|
|
Survivin status
[Time Frame: 6 months]
|
|
Secondary Outcome(s)
|
|
Disease activity (DAS28)
[Time Frame: 6 months]
|
|
Response to treatment
[Time Frame: 6 months]
|
|
Secondary ID(s)
|
|
Survivin in Treatment
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|